Evidence map›Paper›PMID 31894898›Full record

ArticleThe Kaohsiung journal of medical sciences2020

miR-335 modulates Numb alternative splicing via targeting RBM10 in endometrial cancer.

Xiao-Qing Dou, Xiu-Juan Chen, Qun Zhou, Ming-Xiao Wen, Shu-Zhen Zhang, Shi-Qian Zhang

Open access · goldAbstract read
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Alternative splicing and cancer: a systematic review.Signal transduction and targeted therapy · 2021
    Pooled it
  2. miR-34c-5p targets Notch2 to promote fracture healing.Journal of orthopaedic surgery and research · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Advances in MiRNAs Involved in Endometrial Carcinoma.Combinatorial chemistry & high throughput screening · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. MicroRNA-641 Inhibits Endometrial Cancer Progression via Targeting AP1G1.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  17. Article
  18. miRNA-Based Regulation of Alternative RNA Splicing in Metazoans.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Non-Coding RNAs as Prognostic Markers for Endometrial Cancer.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiao-Qing DouDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Xiu-Juan ChenDepartment of Obstetrics and Gynecology, People's Hospital of Rizhao, Rizhao, China.
Qun ZhouDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Ming-Xiao WenDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Shu-Zhen ZhangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Shi-Qian ZhangDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Shandong University, Jinan, China.ORCID https://orcid.org/0000-0001-8552-4871
Zhejiang Chinese Medical University · CNPeople’s Hospital of Rizhao · CN

Funding

The Fundamental Research Funds for Zhejiang province medical and health technology project 2015KYA168
6 · The paper itself

Abstract

Numb is a conserved protein plays important roles in the development of cancer. Two Numb isoforms have been found produced by alternative splicing and play contrast roles in regulating cellular functions. It is reported that the expression of Numb long isoform (Numb-L) was increased in various kinds of cancers, but in endometrial cancer, the condition is still unknown. The level of two Numb transcripts and protein isoforms were detected by semiquantitative polymerase chain reaction and immunoblotting in 47 paired endometrial tumor and adjacent non-tumor control tissues. The level of three alternative splicing related proteins: RBM5, RBM6, and RBM10 was determined by immunoblotting. MiRNAs targeting RBM10 were predicted by bioinformatics tools and their interaction with RBM10 was confirmed by luciferase assay and immunoblotting. The function of miR-335 in endometrial cancer was examined in xenograft mouse model. Numb-L level was increased in tumors and negatively correlated with RBM10 protein level. RBM10 mRNA level was not significantly altered in endometrial tumors suggesting its expression may regulated by post transcriptional regulators such as miRNAs. We identified miR-133a, miR-133b, and miR-335 directly target RBM10, but only miR-335 level increased in tumors and negatively correlated with RBM10 protein level. miR-335 overexpression promoted tumor growth by downregulating RBM10 and upregulating Numb-L level in xenograft mouse model. miR-335 overexpression promoted Numb-L expression via targeting RBM10 in endometrial cancer, which may provide new biomarkers for EC diagnosis.

Indexed as

AdultAlternative SplicingAnimalsBlotting, WesternCell Line, TumorCell ProliferationEndometrial NeoplasmsFemaleHumansMiceMicroRNAsMiddle AgedRNA-Binding ProteinsMicroRNAsMIRN335 microRNA, humanMirn335 microRNA, mouseRBM10 protein, humanRBM10 protein, mouseRNA-Binding Proteinsalternative splicingendometrial cancermicroRNANumb

Identifiers

PMID31894898
PMCPMC11896503
OpenAlexW2998176205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.